Skip to main content
Fig. 1 | European Journal of Medical Research

Fig. 1

From: Comparison of post-COVID-19 vaccination hypermetabolic lymphadenopathy on 18F-fluorodeoxyglucose PET/CT between virus-vector vaccine and mRNA vaccine

Fig. 1

FDG PET/CT after COVID-19 vaccination. A and B A 42-year-old men underwent FDG-PET/CT for colon cancer staging. He received the first dose of the Oxford-AstraZeneca vaccine in the left arm 6 days before the scan. The SUVmax of HLN was 4.27, and the SUVmax of DL was 1.91. C and D A 54-year-old men underwent FDG-PET/CT for evaluation of recurrent colon cancer. He had his first dose of Moderna vaccine in the left arm 42 days before the scan. The SUVmax of HLN was 4.48, and the DL showed no hypermetabolism with SUVmax equal to 0.77. FDG PET/CT, 18F-fluorodeoxyglucose positron emission tomography/computed tomography; COVID-19, coronavirus disease 2019; HLN, hypermetabolic lymphadenopathy; DL, deltoid muscle uptake; SUVmax, maximal standard uptake value

Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us